August J. Troendle, President and CEO of Medpace Holdings, Inc., filed a Form 4 on August 21, 2026, disclosing the sale of common stock on August 19 and August 20, 2026.
Key Highlights
- August 19 sale: Troendle disposed of 15,609 shares of common stock at a weighted average price of $606.47, with individual transactions ranging from $601.29 to $611.42.
- August 20 sale: Troendle disposed of 27,174 shares of common stock at a weighted average price of $618.79, with individual transactions ranging from $606.20 to $626.51.
- Direct ownership following transactions: Troendle directly held 561,195 shares after the August 20 sale.
- Indirect ownership: Troendle indirectly holds 4,733,019 shares through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.
- Transaction basis: Both sales were effected pursuant to a limit order placed during an open window period, according to the filing.
Troendle's Two-Day Share Sale at Medpace Holdings
According to the filing, August J. Troendle, who serves as President and CEO and is identified as a Director and 10% Owner of Medpace Holdings, Inc. (NASDAQ:MEDP), sold a combined 42,783 shares of common stock across two trading days. On August 19, 2026, he disposed of 15,609 shares directly held, leaving him with 588,369 directly owned shares after that transaction. The weighted average sale price for that day was $606.47, covering multiple transactions in the range of $601.29 to $611.42.
On August 20, 2026, Troendle sold an additional 27,174 directly held shares at a weighted average price of $618.79, with individual transaction prices ranging from $606.20 to $626.51. Following this second sale, his direct beneficial ownership stood at 561,195 shares, as reported in the filing. Both sets of transactions are described as having been effected pursuant to a limit order placed during an open window period.
Separately, the filing reports that Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC. The filing states that he "is the sole manager and controlling unit holder of Medpace Investors, LLC" and "has sole voting and investment control with respect to the securities held by MPI," but also notes that he "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein." The filing was signed by Stephen P. Ewald as Attorney-in-Fact for August J. Troendle on August 21, 2026.
What Was Disclosed
The filing discloses two open-market sales of Medpace Holdings common stock by President and CEO August J. Troendle on August 19 and August 20, 2026, totaling 42,783 shares, along with his resulting direct and indirect beneficial ownership positions.




Please wait processing your request...